IXICO boss says Medidata collab is poster child of partnership plans - ICYMI

After IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB) reported a strong first half, with revenue growth and a rising order book pointing to increasing momentum in its core clinical trials business, CEO Bram Goorden joined Proactive to discuss the drivers behind the performance. These included contract wins, scaling analytics, and expansion into later-stage studies.